News

The new patent will provide Apricus Bio protection for Vitaros until 2026. The MPO has issued a ‘notice of allowance for the patent entitled, ‘Topical Stabilized Prostaglandin E

PCMT is available through the company’s CLIA (Clinical Laboratory Improvement Amendments) lab in Aurora, Colorado. Utilizing its cancerization field effect to identify molecular changes and enable detection of

Pharmasset will assess PSI-7977 400mg QD with pegylated interferon and ribavirin in patients with HCV genotype 1, 4, 5 or 6 who have not been treated previously. The

The company has posted net loss of $7.74m, or $0.43 loss per diluted share, as compared to net loss of $9.15m, or $0.62 loss per diluted share, for

As per the agreement, Merck will give development license for its clinical-stage compounds Pruvanserin and Sarizotan to Newron and will hold buy back options for each of the

As per the terms of the agreement, GSK will transfer the ownership of penicillin manufacturing site in Bristol, Tennessee and the rights of Augmentin and Amoxil brands in

Motesanib is an investigational, orally-administered small molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptors, and stem cell factor receptor. The

The Phase 2 study is designed to compare MDV3100 with bicalutamide – a commonly used anti-androgen, and is expected to enroll approximately 370 patients in North America and

In the first of a two segment Phase 2a trial, 64 patients were enrolled and randomised to receive three doses of ACH-1625 given once daily (200mg, 400mg or